Payment overview · 2025
General Payments
$206.02
11 reported records · 7 companies
Healthcare provider profile · identity verified
Mark Edward Swetz, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ORCHARD PARK, NY · NPI 1013918879
Verified facts
What the public records show
CMS Open Payments records show Mark Edward Swetz, M.D. received $206.02 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.02 | 41.3% | 5 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.18 | 11.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.28 | 10.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.53 | 10.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.16 | 10.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.03 | 8.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.82 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.02 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.41 | 4 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 227 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
227 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 557 | 144 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 520 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 514 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 509 | 146 |
| Metoprolol Succinate | Metoprolol Succinate | 494 | 138 |
| Prednisone | Prednisone | 477 | 214 |
| Lisinopril | Lisinopril | 473 | 124 |
| Omeprazole | Omeprazole | 438 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 410 | 110 |
| Baclofen | Baclofen | 303 | 101 |
| Famotidine | Famotidine | 303 | 105 |
| Metformin Hcl | Metformin Hcl | 276 | 79 |
| Sertraline Hcl | Sertraline Hcl | 276 | 88 |
| Methylprednisolone | Methylprednisolone | 268 | 174 |
| Azithromycin | Azithromycin | 261 | 181 |
| Zolpidem Tartrate | Zolpidem Tartrate | 252 | 38 |
| Furosemide | Furosemide | 249 | 91 |
| Alprazolam | Alprazolam | 245 | 63 |
| Eliquis | Apixaban | 227 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 65 |
| Gabapentin | Gabapentin | 219 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 58 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 180 | 90 |
| Simvastatin | Simvastatin | 171 | 43 |
| Trazodone Hcl | Trazodone Hcl | 161 | 44 |
| Allopurinol | Allopurinol | 160 | 45 |
| Atenolol | Atenolol | 156 | 43 |
| Losartan Potassium | Losartan Potassium | 155 | 45 |
| Ozempic | Semaglutide | 151 | 28 |
| Synthroid | Levothyroxine Sodium | 146 | 26 |
| Glimepiride | Glimepiride | 144 | 40 |
| Ibuprofen | Ibuprofen | 140 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 39 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 129 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 33 |
| Ezetimibe | Ezetimibe | 118 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 35 |
| Cefuroxime | Cefuroxime Axetil | 114 | 79 |
| Jardiance | Empagliflozin | 114 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 111 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 30 |
| Metformin Hcl Er | Metformin Hcl | 104 | 29 |
| Tramadol Hcl | Tramadol Hcl | 101 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 100 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 98 | 66 |
| Pregabalin | Pregabalin | 93 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 21 |
| Spironolactone | Spironolactone | 91 | 30 |
| Clonazepam | Clonazepam | 90 | 16 |
| Levofloxacin | Levofloxacin | 89 | 50 |
| Diazepam | Diazepam | 85 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 13 |
| Meloxicam | Meloxicam | 80 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 17 |
| Irbesartan | Irbesartan | 68 | 16 |
| Amoxicillin | Amoxicillin | 67 | 49 |
| Naproxen | Naproxen | 67 | 25 |
| Glipizide Er | Glipizide | 64 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 16 |
| Xarelto | Rivaroxaban | 61 | 19 |
| Bupropion Xl | Bupropion Hcl | 58 | 23 |
| Warfarin Sodium | Warfarin Sodium | 57 | 14 |
| Hydrocortisone | Hydrocortisone | 56 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 12 |
| Donepezil Hcl | Donepezil Hcl | 53 | 18 |
| Lorazepam | Lorazepam | 53 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 16 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 51 | 30 |
| Propranolol Hcl | Propranolol Hcl | 51 | 11 |
| Potassium Chloride | Potassium Chloride | 49 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 12 |
| Ondansetron Odt | Ondansetron | 48 | 36 |
| Celecoxib | Celecoxib | 47 | 15 |
| Meclizine Hcl | Meclizine Hcl | 47 | 16 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 15 |
| Valacyclovir | Valacyclovir Hcl | 44 | 20 |
| Almotriptan Malate | Almotriptan Malate | 42 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 42 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 39 | 16 |
| Fluconazole | Fluconazole | 39 | 16 |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 38 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Nystatin | Nystatin | 36 | 26 |
| Tobramycin | Tobramycin | 36 | 20 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 35 | 16 |
| Bumetanide | Bumetanide | 34 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Benzonatate | Benzonatate | 30 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 13 |
| Ssd | Silver Sulfadiazine | 21 | 16 |
| Cartia Xt | Diltiazem Hcl | 20 | suppressed |
| Cimetidine | Cimetidine | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Telmisartan | Telmisartan | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.02 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, MOUNJARO, NURTEC ODT, NUZYRA, Ozempic, Rybelsus, TRELEGY ELLIPTA, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error